Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Ophthalmology
•
Vitreoretinal Diseases and Surgery
In your experience, what factors prompt you to switch a patient with diabetic macular edema to Eylea HD?
Related Questions
How do you determine whether to switch to a different anti-VEGF agent or to Ozurdex after a patient with diabetic macular edema fails a series of Avastin?
What is your preferred method for choroidal drainage?
What factors influence your evaluation of surgical candidacy for persistent fetal vasculature, and how do you approach operative management?
How do you incorporate intravitreal methotrexate injections into the management of traumatic retinal detachment repairs?
How do you approach patient selection for starting intravitreal complement inhibitors?
What alternative treatment strategies can be considered for pediatric patients with idiopathic choroidal neovascularization (CNVM) who require q4 week intravitreal anti-VEGF injections?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
How do you manage macular-threatening toxoplasma chorioretinitis in pregnancy?
When should methotrexate injections be initiated for proliferative vitreoretinopathy?
If a patient is legally blind and on hydroxychloroquine, do you still recommend follow up with ophthalmology to monitor for hydroxychloroquine retinal toxicity?
